Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

, rater-blinded study that will compare alemtuzumab to Rebif(R) as first-line therapy for patients with relapsing-remitting multiple sclerosis (MS). The second Phase 3 study, CARE-MS II, also has begun and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Phase 2 Trial Design

The phase 2 trial randomized 334 patients with active relapsing-remitting multiple sclerosis at 49 medical centers in Europe and the United States. Patients in the trial were treated with alemtuzumab at one of two doses (12 or 24/mg per day intravenously for five days at initial treatment, and three days of re-treatment after 12 months with an option to treat again at 24 months), or interferon beta-1a (44 mcg administered by subcutaneous injection three times per week, as indicated in its product label).

The randomized trial compared the efficacy of alemtuzumab with interferon beta-1a using two primary endpoints: the rate of relapse of MS symptoms, and the time to Sustained Accumulation of Disability over six months as measured by Expanded Disability Status Scale [EDSS]. Efficacy assessments were made by independent neurologists blinded to therapy.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the recently-initiated CARE-MS I Phase 3 trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, debilitating disease in which the immune system attacks the person's brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can pr
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Global ... to reach USD 24.7 billion by 2022, according ... Inc. Growing prevalence of neurological and musculoskeletal disorders ... over the forecast period. The presence of efficient ... advancement in the technologies coupled with implementation of ...
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)... 2015  Dr. Cal Robinson , Psy.D., ... Center today, providing patients with new methods ... through psychological counseling and treatment programs. ... medical psychologist with an extensive career in pain ... from assessment and treatment of behavioral medicine disorders ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2
... Calif., March 30, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... that management will present a company overview at Needham,s 10th ... a.m. ET at the New York Palace Hotel. ... on the "Investors & Media" section of the Company,s Web ...
... LONDON, March 30, 2011 Silence Therapeutics plc (AIM: ... interference (RNAi) therapeutics company, announces that interim data from ... Company,s lead internal therapeutic candidate, have been accepted for ... Oncology ("ASCO") Annual Meeting.  The meeting will take place ...
Cached Medicine Technology:Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting 2Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting 3
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today welcomed the announcement by OPKO Health that ... Application for a new treatment for chronic kidney disease (CKD) and vitamin D ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... retailer of nutritional supplements, has officially opened the polls for their eleventh ... the following categories:, ,     Brand of the Year (BPI ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los ... in need. Most people know that general health emergencies, such as broken arms or ... of people know where to turn to during a dental emergency. This is important, ...
(Date:8/3/2015)... ... 03, 2015 , ... Social impact organization’s #HelpOneHelpMany approach recognized ... Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in the Innovative ... is to develop technology for the sake of humanity – continues to receive ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Novatus Unveils Milestone Software Release 2
... such as kidney failure and endocrine tumors are among ... the common pain relievers in your medicine cabinet be ... Tel Aviv University,s Sackler Faculty of Medicine and the ... are underlying causes of hypertension, which is a major ...
... Ariz. -- Scientists at Fred Hutchinson Cancer Research ... have discovered a literal ,break through, in pancreatic ... cancer tumors build around themselves have made them ... Hutchinson Center/TGen study published today in the highly-regarded ...
... (HealthDay News) -- Seeing a baby,s face triggers a response ... planning movement, a finding researchers say may indicate a natural ... this pattern in adults who didn,t know the baby and ... have no children of their own. Yet images of a ...
... New evidence links Alzheimer,s disease and diabetes , ... may be linked to insulin resistance, constituting a third ... observations including an increased risk of developing Alzheimer,s disease ... brain tissue of Alzheimer,s disease patients. Though intriguing, the ...
... muscles, and, more specifically, skeletal muscles that are controlled ... cylindrical muscle fibres with a multitude of peripheral nuclei. ... to position nuclei on the edge of muscle fibres. ... understand the reasons behind nuclei layout. Edgar ...
... , TUESDAY, March 20 (HealthDay News) -- The anti-inflammatory ... altitude sickness, according to a new study. Headache, ... the symptoms of altitude sickness, which affects more than ... each year to ski, hike or camp. If ...
Cached Medicine News:Health News:Pain relievers could be spiking your blood pressure 2Health News:Hutchinson Center and TGen scientists discover potential 'break through' in pancreatic cancer 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2Health News:JCI early table of contents for March 26, 2012 2Health News:JCI early table of contents for March 26, 2012 3Health News:JCI early table of contents for March 26, 2012 4Health News:JCI early table of contents for March 26, 2012 5Health News:JCI early table of contents for March 26, 2012 6Health News:New discovery of proteins involved in positioning muscular nuclei 2Health News:Ibuprofen May Ward Off Altitude Sickness 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: